{"id":351956,"date":"2026-11-18T10:28:14","date_gmt":"2026-11-18T04:58:14","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=351956"},"modified":"2026-11-18T10:28:14","modified_gmt":"2026-11-18T04:58:14","slug":"dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/","title":{"rendered":"Top Diagnostics Stocks Compared: Dr Lal PathLabs vs Metropolis vs Thyrocare vs Krsnaa Diagnostics vs Vijaya Diagnostic on Price, Valuation, Q2 FY27 Results and Risks"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Previous close: Dr Lal PathLabs Rs 1,980.20, Metropolis Rs 567.00, Thyrocare Rs 506.95, Krsnaa Diagnostics Rs 518.70, Vijaya Diagnostic Rs 1,467.40.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">This diagnostics stocks compared snapshot checks five names on price, valuation and Q2 FY27 results: Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic. Dr Lal PathLabs is the largest by market capitalisation at Rs 33,431 crore. Thyrocare reports the highest return on equity at 31.66%. Diagnostics chains run different models, so read each multiple next to margins and returns.<\/p>\n<\/p><\/div>\n<p><strong>Diagnostics stocks compared<\/strong> here means Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic on one page, checked on previous close, market value, valuation and the latest quarterly numbers. The group covers five listed diagnostic chains, each with a different mix of home collection, hospital labs and public programmes, which is exactly why a side-by-side look helps.<\/p>\n<p>All five companies have filed their September 2026 quarter, so every result below is Q2 FY27. Diagnostics stocks follow test volumes, pricing, lab capacity and health awareness, so a glance at the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> page and the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> page before you read the tables gives useful backdrop.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=diagnostics-stocks-compared\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Diagnostics_Stocks_Compared_Five_Names_on_the_List\" title=\"Diagnostics Stocks Compared: Five Names on the List\">Diagnostics Stocks Compared: Five Names on the List<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Diagnostics_Stocks_Valuation_Multiples_Returns_and_Payouts\" title=\"Diagnostics Stocks Valuation: Multiples, Returns and Payouts\">Diagnostics Stocks Valuation: Multiples, Returns and Payouts<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Diagnostics_Stocks_Q2_FY27_Results_Revenue_and_Profit_Check\" title=\"Diagnostics Stocks Q2 FY27 Results: Revenue and Profit Check\">Diagnostics Stocks Q2 FY27 Results: Revenue and Profit Check<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Dr_Lal_PathLabs_Results_Snapshot\" title=\"Dr Lal PathLabs Results Snapshot\">Dr Lal PathLabs Results Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Metropolis_Results_Snapshot\" title=\"Metropolis Results Snapshot\">Metropolis Results Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Thyrocare_Results_Snapshot\" title=\"Thyrocare Results Snapshot\">Thyrocare Results Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Krsnaa_Diagnostics_Results_Snapshot\" title=\"Krsnaa Diagnostics Results Snapshot\">Krsnaa Diagnostics Results Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Vijaya_Diagnostic_Results_Snapshot\" title=\"Vijaya Diagnostic Results Snapshot\">Vijaya Diagnostic Results Snapshot<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Diagnostics_Stocks_Compared_Two_at_a_Time_Three_Pairings\" title=\"Diagnostics Stocks Compared Two at a Time: Three Pairings\">Diagnostics Stocks Compared Two at a Time: Three Pairings<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Dr_Lal_PathLabs_vs_Metropolis\" title=\"Dr Lal PathLabs vs Metropolis\">Dr Lal PathLabs vs Metropolis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Thyrocare_vs_Vijaya_Diagnostic\" title=\"Thyrocare vs Vijaya Diagnostic\">Thyrocare vs Vijaya Diagnostic<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Krsnaa_Diagnostics_vs_Dr_Lal_PathLabs\" title=\"Krsnaa Diagnostics vs Dr Lal PathLabs\">Krsnaa Diagnostics vs Dr Lal PathLabs<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Best_Diagnostics_Stocks_for_Each_Type_of_Investor\" title=\"Best Diagnostics Stocks for Each Type of Investor\">Best Diagnostics Stocks for Each Type of Investor<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#What_Is_Driving_Diagnostics_Stocks_Right_Now\" title=\"What Is Driving Diagnostics Stocks Right Now?\">What Is Driving Diagnostics Stocks Right Now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Risks_to_Weigh_When_You_Compare_Diagnostics_Stocks\" title=\"Risks to Weigh When You Compare Diagnostics Stocks\">Risks to Weigh When You Compare Diagnostics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#How_to_Compare_Diagnostics_Stocks_and_Build_a_Shortlist\" title=\"How to Compare Diagnostics Stocks and Build a Shortlist\">How to Compare Diagnostics Stocks and Build a Shortlist<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Conclusion_Diagnostics_Stocks_Compared_at_a_Glance\" title=\"Conclusion: Diagnostics Stocks Compared at a Glance\">Conclusion: Diagnostics Stocks Compared at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Frequently_Asked_Questions_on_Diagnostics_Stocks_Compared\" title=\"Frequently Asked Questions on Diagnostics Stocks Compared\">Frequently Asked Questions on Diagnostics Stocks Compared<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Which_are_the_top_diagnostics_stocks_compared_in_this_article\" title=\"Which are the top diagnostics stocks compared in this article?\">Which are the top diagnostics stocks compared in this article?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Which_diagnostics_stock_has_the_highest_market_capitalisation\" title=\"Which diagnostics stock has the highest market capitalisation?\">Which diagnostics stock has the highest market capitalisation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Which_of_these_diagnostics_stocks_has_the_lowest_price_to_earnings_ratio\" title=\"Which of these diagnostics stocks has the lowest price to earnings ratio?\">Which of these diagnostics stocks has the lowest price to earnings ratio?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Which_diagnostics_stock_has_the_highest_return_on_equity\" title=\"Which diagnostics stock has the highest return on equity?\">Which diagnostics stock has the highest return on equity?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#How_did_diagnostics_stocks_perform_in_Q2_FY27_results\" title=\"How did diagnostics stocks perform in Q2 FY27 results?\">How did diagnostics stocks perform in Q2 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#What_are_the_main_risks_when_you_compare_diagnostics_stocks\" title=\"What are the main risks when you compare diagnostics stocks?\">What are the main risks when you compare diagnostics stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Which_metrics_matter_most_when_you_compare_Diagnostics_stocks\" title=\"Which metrics matter most when you compare Diagnostics stocks?\">Which metrics matter most when you compare Diagnostics stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-vs-krsnaa-diagnostics-vs-vijaya-diagnostic-diagnostics-stocks\/#Which_is_the_best_diagnostics_stock_to_buy_among_these_five\" title=\"Which is the best diagnostics stock to buy among these five?\">Which is the best diagnostics stock to buy among these five?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Diagnostics_Stocks_Compared_Five_Names_on_the_List\"><\/span><strong>Diagnostics Stocks Compared: Five Names on the List<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The diagnostics stocks compared here are Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic. Dr Lal PathLabs is the largest by <strong>market capitalisation<\/strong> at Rs 33,431 crore. Previous closes run from Rs 506.95 for Thyrocare to Rs 1,980.20 for Dr Lal PathLabs, which is why a side-by-side look at value rather than price is more useful.<\/p>\n<table>\n<thead>\n<tr>\n<th>Stock<\/th>\n<th>Previous close (Rs)<\/th>\n<th>Market cap (Rs crore)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr Lal PathLabs<\/a><\/td>\n<td>1,980.20<\/td>\n<td>33,431<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/metropolis\/metropolis-healthcare-ltd-share-price-today\">Metropolis<\/a><\/td>\n<td>567.00<\/td>\n<td>11,696<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/thyrocare\/thyrocare-technologies-ltd-share-price-today\">Thyrocare<\/a><\/td>\n<td>506.95<\/td>\n<td>7,942<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/krsnaa\/krsnaa-diagnostics-ltd-share-price-today\">Krsnaa Diagnostics<\/a><\/td>\n<td>518.70<\/td>\n<td>1,715<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/vijaya\/vijaya-diagnostic-centre-ltd-share-price-today\">Vijaya Diagnostic<\/a><\/td>\n<td>1,467.40<\/td>\n<td>14,528<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>A quick look at the business behind each ticker puts the numbers in context. Dr Lal PathLabs runs diagnostic labs and collection centres, while Metropolis runs diagnostic labs. Thyrocare runs diagnostic testing labs, and Krsnaa Diagnostics runs diagnostic centres. To compare diagnostics stocks properly, line up <strong>price to earnings<\/strong>, <strong>return on equity<\/strong> and operating margin before forming a view.<\/p>\n<p>Rounding out the group, Vijaya Diagnostic runs diagnostic centres. A fair diagnostics stock comparison looks at what each company actually earns from, not only at the share price. <strong>A lab chain and a public programme specialist belong in separate mental boxes whenever you compare diagnostics stocks fairly.<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Diagnostics_Stocks_Valuation_Multiples_Returns_and_Payouts\"><\/span><strong>Diagnostics Stocks Valuation: Multiples, Returns and Payouts<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Krsnaa Diagnostics trades at the lowest <strong>price to earnings<\/strong> ratio in this group at 17.48. Thyrocare reports the highest <strong>return on equity<\/strong> at 31.66%. Krsnaa Diagnostics has the lowest <strong>price to book<\/strong> value at 1.65. These <strong>diagnostics stocks valuation<\/strong> readings come from the previous close and the latest reported financials. That is the idea behind this <strong>diagnostics stocks compared<\/strong> table: <strong>price to earnings<\/strong> and <strong>return on equity<\/strong> sit side by side so a high or low reading stands out at once.<\/p>\n<table>\n<thead>\n<tr>\n<th>Stock<\/th>\n<th>Price to earnings<\/th>\n<th>Price to book<\/th>\n<th>ROE (%)<\/th>\n<th>Dividend yield (%)<\/th>\n<th>Debt to equity<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Dr Lal PathLabs<\/td>\n<td>56.86<\/td>\n<td>12.18<\/td>\n<td>21.32<\/td>\n<td>1.03<\/td>\n<td>0.09<\/td>\n<\/tr>\n<tr>\n<td>Metropolis<\/td>\n<td>51.90<\/td>\n<td>7.13<\/td>\n<td>13.66<\/td>\n<td>0.89<\/td>\n<td>0.16<\/td>\n<\/tr>\n<tr>\n<td>Thyrocare<\/td>\n<td>55.44<\/td>\n<td>14.35<\/td>\n<td>31.66<\/td>\n<td>2.81<\/td>\n<td>0.10<\/td>\n<\/tr>\n<tr>\n<td>Krsnaa Diagnostics<\/td>\n<td>17.48<\/td>\n<td>1.65<\/td>\n<td>9.45<\/td>\n<td>0.38<\/td>\n<td>0.57<\/td>\n<\/tr>\n<tr>\n<td>Vijaya Diagnostic<\/td>\n<td>71.31<\/td>\n<td>13.74<\/td>\n<td>19.26<\/td>\n<td>0.14<\/td>\n<td>0.48<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Price to earnings, return on equity, debt to equity and <strong>dividend yield<\/strong> give the clearest picture of valuation, returns and balance sheet room across the five names. <strong>Earnings per share<\/strong> and <strong>book value<\/strong> per share are the building blocks behind price to earnings and <strong>price to book<\/strong>, so a glance at both in each filing is time well spent. A simple diagnostics stock comparison like this one is only as useful as the context behind it, which is why operating margin is worth checking as well.<\/p>\n<p>In this group, price to earnings runs from 17.48 for Krsnaa Diagnostics to 71.31 for Vijaya Diagnostic. Thyrocare offers the highest <strong>dividend yield<\/strong> at 2.81%. The sector benchmark for price to earnings is 62.49, and every stock in the table can be measured against that figure. The industry price to earnings is a handy anchor: a stock above it is priced for faster growth, and one below it is priced for steadier earnings. <strong>A well-built diagnostics stock comparison also notes that test volumes can move with seasonal illness.<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Diagnostics_Stocks_Q2_FY27_Results_Revenue_and_Profit_Check\"><\/span><strong>Diagnostics Stocks Q2 FY27 Results: Revenue and Profit Check<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>All of the five diagnostics stocks compared have filed Q2 FY27 numbers. Krsnaa Diagnostics posted the fastest revenue growth at 31.9% year on year. Metropolis showed the sharpest rise in net profit at 42.7%. Read revenue first and <strong>quarterly profit<\/strong> second, since the two together show how much of the growth reaches shareholders. Treat the Q2 FY27 numbers in this <strong>diagnostics stocks compared<\/strong> review as a snapshot of one quarter, not a verdict on any diagnostics company.<\/p>\n<table>\n<thead>\n<tr>\n<th>Stock<\/th>\n<th>Q2 FY27 revenue (Rs crore)<\/th>\n<th>Q2 FY26 revenue (Rs crore)<\/th>\n<th>Q2 FY27 net profit (Rs crore)<\/th>\n<th>Q2 FY26 net profit (Rs crore)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Dr Lal PathLabs<\/td>\n<td>908.2<\/td>\n<td>755.4<\/td>\n<td>193.9<\/td>\n<td>152.2<\/td>\n<\/tr>\n<tr>\n<td>Metropolis<\/td>\n<td>505.3<\/td>\n<td>430.1<\/td>\n<td>75.5<\/td>\n<td>52.9<\/td>\n<\/tr>\n<tr>\n<td>Thyrocare<\/td>\n<td>274.4<\/td>\n<td>219.6<\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Krsnaa Diagnostics<\/td>\n<td>277.1<\/td>\n<td>210.2<\/td>\n<td>24.6<\/td>\n<td>23.9<\/td>\n<\/tr>\n<tr>\n<td>Vijaya Diagnostic<\/td>\n<td>260.3<\/td>\n<td>207.8<\/td>\n<td>59.5<\/td>\n<td>43.3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_Results_Snapshot\"><\/span><strong>Dr Lal PathLabs Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Lal PathLabs reported Q2 FY27 revenue of <strong>Rs 908.2 crore<\/strong>, compared with <strong>Rs 755.4 crore<\/strong> a year earlier, a rise of <strong>20.2%<\/strong>. Net profit rose 27.4% to Rs 193.9 crore from Rs 152.2 crore. Operating margin expanded to 36.0% from 34.1% a year ago.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Metropolis_Results_Snapshot\"><\/span><strong>Metropolis Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the September 2026 quarter, Metropolis booked revenue of <strong>Rs 505.3 crore<\/strong> against <strong>Rs 430.1 crore<\/strong> in the same quarter last year, a rise of <strong>17.5%<\/strong>. Net profit rose 42.7% to Rs 75.5 crore from Rs 52.9 crore. Operating margin expanded to 28.7% from 25.4% a year ago.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Thyrocare_Results_Snapshot\"><\/span><strong>Thyrocare Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Thyrocare&#8217;s Q2 FY27 top line stood at <strong>Rs 274.4 crore<\/strong>, versus <strong>Rs 219.6 crore<\/strong> in Q2 FY26, a rise of <strong>25.0%<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Krsnaa_Diagnostics_Results_Snapshot\"><\/span><strong>Krsnaa Diagnostics Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Krsnaa Diagnostics reported Q2 FY27 revenue of <strong>Rs 277.1 crore<\/strong>, compared with <strong>Rs 210.2 crore<\/strong> a year earlier, a rise of <strong>31.9%<\/strong>. Net profit rose 2.7% to Rs 24.6 crore from Rs 23.9 crore. <strong>Earnings per share<\/strong> for the quarter rose to Rs 7.54 from Rs 7.25.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Vijaya_Diagnostic_Results_Snapshot\"><\/span><strong>Vijaya Diagnostic Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the September 2026 quarter, Vijaya Diagnostic booked revenue of <strong>Rs 260.3 crore<\/strong> against <strong>Rs 207.8 crore<\/strong> in the same quarter last year, a rise of <strong>25.3%<\/strong>. Net profit rose 37.4% to Rs 59.5 crore from Rs 43.3 crore. Operating margin expanded to 46.1% from 43.7% a year ago. <strong>Earnings per share<\/strong> for the quarter rose to Rs 5.76 from Rs 4.20.<\/p>\n<p>Test volumes, pricing and lab capacity shape earnings, so each chain needs a look at its own results, so profit can look different from revenue in a single quarter. That is why a diagnostics stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, a <strong>diagnostics stocks compared<\/strong> review becomes a map of the sector rather than a price list. When you compare diagnostics stocks after each result season, track how operating margin changes from one quarter to the next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Diagnostics_Stocks_Compared_Two_at_a_Time_Three_Pairings\"><\/span><strong>Diagnostics Stocks Compared Two at a Time: Three Pairings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare diagnostics stocks two at a time.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_vs_Metropolis\"><\/span><strong>Dr Lal PathLabs vs Metropolis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Lal PathLabs and Metropolis are two of the largest listed diagnostic chains. Dr Lal PathLabs is about 2.9 times the size of Metropolis by <strong>market capitalisation<\/strong>, at Rs 33,431 crore against Rs 11,696 crore. On price to earnings, Metropolis carries the lower multiple at 51.90 against 56.86 for Dr Lal PathLabs. Dr Lal PathLabs reports the higher return on equity, at 21.32% against 13.66% for Metropolis. Two leaders with different city mixes, so read margins next to valuation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Thyrocare_vs_Vijaya_Diagnostic\"><\/span><strong>Thyrocare vs Vijaya Diagnostic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Thyrocare runs a centralised testing model, while Vijaya runs a network of centres. On price to earnings, Thyrocare carries the lower multiple at 55.44 against 71.31 for Vijaya Diagnostic. Thyrocare reports the higher return on equity, at 31.66% against 19.26% for Vijaya Diagnostic. For dividend income, Thyrocare offers 2.81% against 0.14% at Vijaya Diagnostic. Two models with different cost structures, so compare returns first.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Krsnaa_Diagnostics_vs_Dr_Lal_PathLabs\"><\/span><strong>Krsnaa Diagnostics vs Dr Lal PathLabs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Krsnaa serves public health programmes, while Dr Lal PathLabs serves private patients. Dr Lal PathLabs reports the higher return on equity, at 21.32% against 9.45% for Krsnaa Diagnostics. For dividend income, Dr Lal PathLabs offers 1.03% against 0.38% at Krsnaa Diagnostics. In Q2 FY27, Krsnaa Diagnostics grew revenue faster, at 31.9% year on year against 20.2% for Dr Lal PathLabs. A public programme specialist and a private leader differ in customers, so read returns together.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Best_Diagnostics_Stocks_for_Each_Type_of_Investor\"><\/span><strong>Best Diagnostics Stocks for Each Type of Investor<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>People who ask for the <strong>best diagnostics stocks<\/strong> often have very different goals, so here is who leads on each measure today, row by row. Any <strong>diagnostics stocks compared<\/strong> table can mislead if you stop at one row, because each diagnostics company leads on a different measure.<\/p>\n<table>\n<thead>\n<tr>\n<th>If you care most about<\/th>\n<th>Start your research with<\/th>\n<th>The number<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Lowest price to earnings<\/td>\n<td>Krsnaa Diagnostics<\/td>\n<td>17.48<\/td>\n<\/tr>\n<tr>\n<td>Highest return on equity<\/td>\n<td>Thyrocare<\/td>\n<td>31.66%<\/td>\n<\/tr>\n<tr>\n<td>Highest dividend yield<\/td>\n<td>Thyrocare<\/td>\n<td>2.81%<\/td>\n<\/tr>\n<tr>\n<td>Lowest price to book value<\/td>\n<td>Krsnaa Diagnostics<\/td>\n<td>1.65<\/td>\n<\/tr>\n<tr>\n<td>Largest by market capitalisation<\/td>\n<td>Dr Lal PathLabs<\/td>\n<td>Rs 33,431 crore<\/td>\n<\/tr>\n<tr>\n<td>Fastest Q2 FY27 revenue growth<\/td>\n<td>Krsnaa Diagnostics<\/td>\n<td>31.9%<\/td>\n<\/tr>\n<tr>\n<td>Sharpest Q2 FY27 net profit rise<\/td>\n<td>Metropolis<\/td>\n<td>42.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>No single name tops every row, which is exactly why a diagnostics stock comparison helps. Margins, returns and valuation point to different companies, so decide what matters most to you before you rank the numbers.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Driving_Diagnostics_Stocks_Right_Now\"><\/span><strong>What Is Driving Diagnostics Stocks Right Now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnostic chains earn from tests that people book regularly, so readers study them as a steady healthcare theme. Knowing what moves test volumes and pricing helps you compare diagnostics stocks with the right questions in mind.<\/p>\n<p>Test volumes, pricing and lab capacity decide earnings, so growth in patient visits matters. A good <strong>diagnostics stocks compared<\/strong> routine therefore tracks test volumes, pricing and quarterly results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Weigh_When_You_Compare_Diagnostics_Stocks\"><\/span><strong>Risks to Weigh When You Compare Diagnostics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnostics stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Every diagnostics stock comparison has blind spots, and for this group the biggest is test volumes and pricing.<\/p>\n<p>Because test volumes, pricing and quarterly results drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this <strong>diagnostics stocks compared<\/strong> guide a balanced starting point.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Compare_Diagnostics_Stocks_and_Build_a_Shortlist\"><\/span><strong>How to Compare Diagnostics Stocks and Build a Shortlist<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start by deciding which diagnostic model you want exposure to, because each reads the market differently. Readers who follow test volumes, pricing and quarterly results find the group easier to track. Done step by step, this <strong>diagnostics stocks compared<\/strong> routine becomes repeatable rather than a one-off exercise.<\/p>\n<p>Then check valuation and returns, because the five names rarely trade on the same multiple. A centralised testing lab next to a centre network shows how the business behind each price changes the numbers. Keep the shortlist of <strong>best diagnostics stocks<\/strong> short enough that you can actually follow each company&#8217;s quarterly results.<\/p>\n<p>The Univest stock screener lets you filter diagnostics stocks by <strong>market capitalisation<\/strong>, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this <strong>diagnostics stocks compared<\/strong> page after the next set of results to see which numbers have moved.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live diagnostics stock data<\/strong><\/a><\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track these diagnostics stocks live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Diagnostics_Stocks_Compared_at_a_Glance\"><\/span><strong>Conclusion: Diagnostics Stocks Compared at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>diagnostics stocks compared<\/strong> review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Dr Lal PathLabs leads on size and Thyrocare leads on return on equity, while the others bring their own strengths. Treat the <strong>diagnostics stocks Q2 FY27 results<\/strong> and <strong>diagnostics stocks valuation<\/strong> tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare diagnostics stocks again next quarter, the same checklist of price to earnings, return on equity and operating margin will work.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Diagnostics_Stocks_Compared\"><\/span><strong>Frequently Asked Questions on Diagnostics Stocks Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_top_diagnostics_stocks_compared_in_this_article\"><\/span><strong>Which are the top diagnostics stocks compared in this article?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The diagnostics stocks compared in this article are Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, giving you a quick, even-handed view of the group ahead of any detailed filing review.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_diagnostics_stock_has_the_highest_market_capitalisation\"><\/span><strong>Which diagnostics stock has the highest market capitalisation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among the five names, Dr Lal PathLabs has the highest market capitalisation at Rs 33,431 crore. Vijaya Diagnostic follows at Rs 14,528 crore. The figure reflects what the market is paying for the whole company today, and it will change as prices move, so refresh it before you decide.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_diagnostics_stocks_has_the_lowest_price_to_earnings_ratio\"><\/span><strong>Which of these diagnostics stocks has the lowest price to earnings ratio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> On diagnostics stocks valuation, Krsnaa Diagnostics has the lowest price to earnings ratio among these diagnostics stocks at 17.48, based on the latest reported earnings. Vijaya Diagnostic sits at the other end at 71.31. The lowest ratio is not a verdict on the stock, since earnings growth and quality decide whether a multiple is fair.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_diagnostics_stock_has_the_highest_return_on_equity\"><\/span><strong>Which diagnostics stock has the highest return on equity?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Thyrocare reports the highest return on equity in this group at 31.66%. A higher return on equity points to a company that turns shareholder funds into profit efficiently. Check the trend over time and the debt level before leaning on a single reading.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_diagnostics_stocks_perform_in_Q2_FY27_results\"><\/span><strong>How did diagnostics stocks perform in Q2 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> All of the five names have filed Q2 FY27 numbers in our data. Krsnaa Diagnostics recorded the fastest revenue growth at 31.9% year on year. Metropolis showed the sharpest net profit rise at 42.7%. For diagnostics stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_when_you_compare_diagnostics_stocks\"><\/span><strong>What are the main risks when you compare diagnostics stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Diagnostics stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Keep an eye on test volumes, pricing and quarterly results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_metrics_matter_most_when_you_compare_Diagnostics_stocks\"><\/span><strong>Which metrics matter most when you compare Diagnostics stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue growth, operating margin, return on equity and price to earnings matter most here. Compare each multiple with the company&#8217;s own test volume trend. Read each filing for volume and pricing commentary.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_is_the_best_diagnostics_stock_to_buy_among_these_five\"><\/span><strong>Which is the best diagnostics stock to buy among these five?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The best Diagnostics stock depends on which diagnostic model you want exposure to, because the five names differ on all of these. On the numbers in this article, Dr Lal PathLabs has the largest market capitalisation; Krsnaa Diagnostics has the lowest price to earnings; Thyrocare has the highest return on equity as well as the highest dividend yield. The leaders change from row to row, so no stock stands out on everything, and this article is not advice. Shortlist from the tables, verify with the latest filings, and consult a SEBI-registered advisor, since time horizon and risk appetite matter most.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the top diagnostics stocks compared in this article?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The diagnostics stocks compared in this article are Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, giving you a quick, even-handed view of the group ahead of any detailed filing review.\"}},{\"@type\":\"Question\",\"name\":\"Which diagnostics stock has the highest market capitalisation?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among the five names, Dr Lal PathLabs has the highest market capitalisation at Rs 33,431 crore. Vijaya Diagnostic follows at Rs 14,528 crore. The figure reflects what the market is paying for the whole company today, and it will change as prices move, so refresh it before you decide.\"}},{\"@type\":\"Question\",\"name\":\"Which of these diagnostics stocks has the lowest price to earnings ratio?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"On diagnostics stocks valuation, Krsnaa Diagnostics has the lowest price to earnings ratio among these diagnostics stocks at 17.48, based on the latest reported earnings. Vijaya Diagnostic sits at the other end at 71.31. The lowest ratio is not a verdict on the stock, since earnings growth and quality decide whether a multiple is fair.\"}},{\"@type\":\"Question\",\"name\":\"Which diagnostics stock has the highest return on equity?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Thyrocare reports the highest return on equity in this group at 31.66%. A higher return on equity points to a company that turns shareholder funds into profit efficiently. Check the trend over time and the debt level before leaning on a single reading.\"}},{\"@type\":\"Question\",\"name\":\"How did diagnostics stocks perform in Q2 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"All of the five names have filed Q2 FY27 numbers in our data. Krsnaa Diagnostics recorded the fastest revenue growth at 31.9% year on year. Metropolis showed the sharpest net profit rise at 42.7%. For diagnostics stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks when you compare diagnostics stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Diagnostics stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Keep an eye on test volumes, pricing and quarterly results.\"}},{\"@type\":\"Question\",\"name\":\"Which metrics matter most when you compare Diagnostics stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue growth, operating margin, return on equity and price to earnings matter most here. Compare each multiple with the company's own test volume trend. Read each filing for volume and pricing commentary.\"}},{\"@type\":\"Question\",\"name\":\"Which is the best diagnostics stock to buy among these five?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The best Diagnostics stock depends on which diagnostic model you want exposure to, because the five names differ on all of these. On the numbers in this article, Dr Lal PathLabs has the largest market capitalisation; Krsnaa Diagnostics has the lowest price to earnings; Thyrocare has the highest return on equity as well as the highest dividend yield. The leaders change from row to row, so no stock stands out on everything, and this article is not advice. Shortlist from the tables, verify with the latest filings, and consult a SEBI-registered advisor, since time horizon and risk appetite matter most.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Compare Dr Lal PathLabs, Metropolis, Thyrocare, Krsnaa Diagnostics and Vijaya Diagnostic on price, valuation and Q2 FY27 results in one place, with the risks to check before you invest.<\/p>\n","protected":false},"author":34,"featured_media":351954,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[21546,21545,21547,21548],"class_list":["post-351956","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-diagnostics-stocks","tag-diagnostics-stocks-compared","tag-diagnostics-stocks-q2-fy27-results","tag-diagnostics-stocks-valuation"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["351954"],"rank_math_title":["Diagnostics Stocks: Lal PathLabs vs Metropolis vs Thyrocare"],"rank_math_description":["Diagnostics stocks compared on price, valuation and Q2 FY27 results: Dr Lal PathLabs, Metropolis, Thyrocare and more, with risks to check."],"rank_math_focus_keyword":["diagnostics stocks compared"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/top-diagnostics-stocks-compared-dr-lal-pathlabs-vs-metropolis-vs-thyrocare-vs-1.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/351956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=351956"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/351956\/revisions"}],"predecessor-version":[{"id":351957,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/351956\/revisions\/351957"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/351954"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=351956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=351956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=351956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}